Board Change • Jul 29
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairwoman of the Board Fu-Feng Kuo is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 02
Jyong Biotech Showcases Botanical Drug Portfolio At BIO 2026 International Convention Jyong Biotech Ltd. participated in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026. Jyong Biotech once again exhibited at the Taiwan Pavilion. The Company conducted in-depth discussions with global pharmaceutical companies, investment institutions, and industry partners and had the opportunity to present the Company and its assets to them. During the convention, Jyong Biotech presented its botanical new drug candidate, Botreso (API-1), to international pharmaceutical companies as the Company continues advancing global licensing discussions. Targeting benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), the Company has conducted four Phase III clinical trials for Botreso across the United States and Taiwan. The Company believes the drug candidate offers a potentially attractive solution for long-term treatment needs, backed by its proven safety, tolerability, and clinical profile. Driven by an aging global population and rising obesity rates, the BPH and LUTS market continues to expand, with the number of BPH patients projected to grow by 35% to 40% between 2021 and 2035 according to the Global Burden of Disease (GBD 2021) study and BMC Urology. Jyong Biotech is accelerating its New Drug Application (NDA) preparations and global licensing plans. Supported by initial licensing agreement and active discussions with several pharmaceutical partners, the Company aims to expedite commercialization in key markets—including the US, Europe, and Asia—through regional licensing and strategic alliances. As of the date of this press release, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments. Announcement • Apr 30
Jyong Biotech Ltd. announced delayed 20-F filing On 04/29/2026, Jyong Biotech Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. 
